Remunerated pharmacy clinical care services

Added June 20, 2020

Citation: Houle SK, Grindrod KA, Chatterley T, et al. Paying pharmacists for patient care: a systematic review of remunerated pharmacy clinical care services. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada 2014 Jul;147(4):209-32.

What is this? The COVID-19 pandemic is placing a great strain on healthcare services and resources. Existing research on strategies, such as remunerated pharmacist clinical care programmes, may provide useful information for policy makers.

In this update of their systematic review that had been published in 2008, the authors searched for studies of remunerated pharmacist clinical care programmes and services. They restricted their searches to articles published in English and did the updating search in December 2012. They included information on 60 new remunerated programs that covered a range of areas, including emergency contraption counseling, minor ailments schemes and comprehensive medication management.

What was found: Paying pharmacists for patient clinical care was highly variable, with few programs reporting program outcomes.

The most common remunerated pharmacy clinical care service was for completion of a medication review.

Pharmacist services were effective for smoking cessation, identifying and resolving drug-related issues and improving clinical parameters in chronic disease.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.